Studies report up to 18% of patients aged ≥60 years old with heart failure with preserved ejection fraction (HFpEF),1 and up to 18% of patients with hypertrophic cardiomyopathy and left ventricular hypertrophy2–4 had transthyretin amyloid cardiomyopathy (ATTR-CM). Clinical expert Dr Kate Gatenby highlights this and gives an overview of the causes, diagnosis and best practices in the management of patients with ATTR-CM.
References
- Bennani SY et al. Int J Cardiovasc Imaging 2016;32:1403–13
- Tini G et al. Eur J Clin Invest 2021;51:e13665
- Maurizi N et al. Int J Cardiol 2020;300:191–5
- Vermeer AMC et al. Amyloid 2017;24:87–91
